Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16N2O2S2 |
Molecular Weight | 284.398 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
SCCNC(=O)C1=CC(=CC=C1)C(=O)NCCS
InChI
InChIKey=JUTBAVRYDAKVGQ-UHFFFAOYSA-N
InChI=1S/C12H16N2O2S2/c15-11(13-4-6-17)9-2-1-3-10(8-9)12(16)14-5-7-18/h1-3,8,17-18H,4-7H2,(H,13,15)(H,14,16)
Molecular Formula | C12H16N2O2S2 |
Molecular Weight | 284.398 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Emeramide or Irminix® (N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)) is a lipid-soluble thiol-redox antioxidant and heavy metal chelator. Orphan Drug Designation has been granted for the prevention and treatment of mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed and found Irminix® to be effective and safe with no adverse effects. A Phase 2a clinical trial for the treatment of chronic obstructive pulmonary disease has been completed in summer of 2018 and found Irminix® to be safe with no adverse effects.
CNS Activity
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:11:22 GMT 2023
by
admin
on
Sat Dec 16 17:11:22 GMT 2023
|
Record UNII |
4U7K5X4ANS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
367312
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1864
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BDTH2
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
DB12192
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
9949
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
DTXSID10610932
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
351994-94-0
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
C166785
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
100000177193
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
4U7K5X4ANS
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY | |||
|
21133161
Created by
admin on Sat Dec 16 17:11:23 GMT 2023 , Edited by admin on Sat Dec 16 17:11:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INNOVATOR->PARENT | |||
|
TARGET->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|